Identification of Prognostic lncRNA Related to the Immune Microenvironment of Soft Tissue Sarcoma

Table 6

Univariate Cox analysis of clinicopathological factors in patients with DFS-related soft tissue sarcoma.

ID	HR	HR.95L	HR.95H	value
Risk	2.509702365	1.743348261	3.612936155	7.43-07
Age	1.010257968	0.99759091	1.023085868	0.112898635
Type 1	0.805277923	0.515808804	1.257195552	0.340646916
Type 2	0.728409377	0.424318464	1.250429256	0.250402178
Type 3	0.80790002	0.45612612	1.430969228	0.464561685
Metastasis	4.937153189	3.140400876	7.761901289	4.60E-12
Race 1	2.121508392	0.264322128	17.02769987	0.479070219
Race 2	1.913142406	0.265587372	13.78120443	0.519606531
Postoperative_radiotherapy	1.169024353	0.783807692	1.743562804	0.443870378
Margin	2.084657548	1.422072136	3.055961075	0.000167028
Sex	1.089657382	0.766928708	1.548192416	0.631832584
Tumor tissue site 1	0.914504601	0.578235491	1.446328837	0.702367293
Tumor tissue site 2	1.006297116	0.66911367	1.513395902	0.975947716

Type 1: dedifferentiated liposarcoma; type 2: leiomyosarcoma; type 3: undifferentiated peomorphic sarcoma/malignant fibrous histiocytoma/high-grade spindle cell sarcoma; race 1: black; race 2: white; tumor tissue site 1: extremity; tumor tissue ste 2: retroperitoneum/upper abdominal; DFS: disease-free survival; HR: hazard ratio.